Site Editor

Gregory J. Riely, MD, PhD

Advertisement

Advertisement

Medical Literature

ALK+ NSCLC Presents as Rare Mediastinal Mass in Case Study

News

AACR 2025: Divarasib Plus Migoprotafib Combination Treatment KRAS G12C-Positive NSCLC

News

AACR 2025: Updated Results From HORIZON-Lung

Medical Literature

Enhancing Staging Accuracy for NSCLC Using Artificial Neural Networks

Medical Literature

Using Radiogenomic Signatures to Predict Survival in Patients With NSCLC and Brain Metastases

News

Advanced NSCLC: Targeting the CD73/Adenosine Pathway

News

Could Computable Phenotypes Determine Eligibility for Lung Cancer Screening?

Raffaele Califano, MD, on EGFR-Mutant Advanced NSCLC: MARIPOSA-2

Dominique Michaud, ScD, on DNA Methylation Patterns and Lung Cancer Detection

View More

Advertisement

JNCCN Spotlights

Repotrectinib for ROS1-Positive NSCLC

(NEW Update) Nivolumab in NSCLC

(NEW Update) Pembrolizumab in NSCLC

Dabrafenib + Trametinib (Tafinlar + Mekinist)

(UPDATE) Nivolumab (Opdivo) in NSCLC

Sotorasib

View More

More

News

AACR 2025: Updated Results From HORIZON-Lung

Can Deep Learning Models Predict Immunotherapy Response in Advanced NSCLC?

Advanced NSCLC: Targeting the CD73/Adenosine Pathway

AACR 2025: Divarasib Plus Migoprotafib Combination Treatment KRAS G12C-Positive NSCLC

FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC

Study Finds Potential Clinical Use of EGFR TKIs in BRAF Class 3–Mutated NSCLC

Increased Risks of Lung Cancer Among Those With Higher Genetic Sensitivity to Stress

Mobocertinib vs Chemotherapy in EGFR Exon 20 Insertion–Positive Advanced NSCLC

View More

Advertisement

Published

Medical Literature

Wild-Type EGFR NSCLC: Folk Remedy Plus EGFR Tyrosine Kinase Inhibitors Under Study

Treatment-Related Hepatotoxicity in NSCLC: Are All KRAS G12C Inhibitors Created Equal?

Impact of Timely Comprehensive Genomic Profiling for Patients With Advanced NSCLC

Survival and Immune Checkpoint Inhibitor Efficacy in KRAS-Mutated NSCLC

View More

Ongoing

CE Activities

Improving Lung Cancer Care Through Understanding the Patient Experience

Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

View More

Available

Clinical Trials

LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy

An Open-Label, Randomized, Multicenter, Phase III Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

Study of Avutometinib (VS-6766) Plus Adagrasib in KRAS G12C NSCLC Patients

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2025 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.